CurcumPedALL: Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia

Sponsor
Ain Shams University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05045443
Collaborator
(none)
60
1
2
12.3
4.9

Study Details

Study Description

Brief Summary

Assessment of of the biological effects of curcumin on microbiota in children with acute lymphoblastic leukemia

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Assessment of the safety of curcumin, which is the most active constituent of the ground rhizome of the Curcuma longa plant, in children with acute lymphoblastic leukemia patients (ALL) in maintenance phase of chemotherapy through the assessment of the any reported adverse event (AE). And assessment of the curcumin effect on health by eliminating intestinal microflora dysbiosis

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia
Actual Study Start Date :
Aug 22, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Curcumin

Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea

Drug: Curcumin
Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
Other Names:
  • Tumeric curcumin
  • Dietary Supplement: Standard of Care
    As per institution protocol for Standard of nutritional Care

    Placebo Comparator: Standard of nutritional care

    Standard of nutritional support care

    Dietary Supplement: Standard of Care
    As per institution protocol for Standard of nutritional Care

    Outcome Measures

    Primary Outcome Measures

    1. Determine the Safety of curcumin in pediatric patients with ALL. [4 weeks]

      Percentage of patients who developed adverse event

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Children aged from 1 year to 18 years Children with proven ALL diagnosed by bone marrow aspirate and immunephenotyping Patients in the maintenance phase week1

    Exclusion Criteria:

    Children with other maliganacies, Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including to sulfasalazine, warfarin, clopidogrel, aspirin, antacids, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Pediatric Hematology Oncology and BMT Unit, Faculty of Medicine Ain Shams University Cairo Non-US Egypt 11566

    Sponsors and Collaborators

    • Ain Shams University

    Investigators

    • Study Chair: Ihab Khairy, M.D, Faculty of Medicine Ain Shams University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Fatma Soliman Elsayed Ebeid, Professor of pediatrics Hematology Oncology and Bone Marrow Transplant, Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT05045443
    Other Study ID Numbers:
    • FMASU MD 134/2021
    First Posted:
    Sep 16, 2021
    Last Update Posted:
    Sep 17, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Fatma Soliman Elsayed Ebeid, Professor of pediatrics Hematology Oncology and Bone Marrow Transplant, Ain Shams University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 17, 2021